ICB International

ICB International is a private biotechnology company based in La Jolla, California developing blood-brain barrier permeable biologics for central nervous system diseases. Its core SMART Molecule Technology Platform, described as Specific Molecular Architecture for Recognition and Therapy, uses miniaturized antibody-mimic molecules designed to cross the blood-brain barrier and bind pathological proteins in the brain. The company is focused primarily on Alzheimer's disease and Parkinson's disease, with additional references to multiple system atrophy, glioblastoma, and broader CNS applications. Public company materials indicate that its SMART molecules are intended for both diagnostic and therapeutic use, and that the company has discussed Phase 1 clinical trial readiness while also describing individual pipeline assets largely in preclinical development. The business appears to be platform-centric, IP-driven, and funded privately.